ELISA News and Research

RSS

SAIC-F selects SAIC-F selects Precision Antibody to provide characterization for reference antibody resource development

Precision Antibody announced today its selection by Science Applications International Corporation-Frederick to provide antibody and antigen characterization, including surface plasmon resonance analysis, for the National Cancer Institute's "Clinical Proteomic Technologies for Cancer" initiative. A goal of the CPTC is to develop a standardized resource of very high-quality, renewable reference antibodies generated against cancer-related proteins. The antibodies will be made available to proteomics researchers, along with characterization data and other information intended to support replication and standardization.

22 Jul 2010

Depression increases cardiovascular problems in men with erectile dysfunction

A new study in the Journal of Sexual Medicine found that the presence of depressive symptoms in men with erectile dysfunction constitutes a risk factor for a major cardiovascular event.

13 Jul 2010

Biomagnetics, LANL collaborate to develop device for tuberculosis diagnosis

Biomagnetics Diagnostics Corp., a developer of revolutionary technology for diagnostic systems for HIV, hepatitis, tuberculosis and malaria detection, today announced the signing of an agreement with Los Alamos National Security, LLC where Los Alamos National Laboratory's scientific and engineering staffs will attempt to identify new potential human tuberculosis biomarkers and will develop a validated assay to detect human tuberculosis using a currently known biomarker to be used in combination with the waveguide-based optical biosensor platform.

9 Jul 2010

Aethlon Medical files provisional patent on behalf of ESI for exosome detection assay

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has filed a provisional patent on behalf of its wholly owned subsidiary Exosome Sciences, Inc. (ESI), relating to the development of an assay that will allow researchers to detect exosomes in blood and other fluids.

8 Jul 2010

Aushon BioSystems introduces new Human multiplex biomarker panels

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, has launched new Human multiplex biomarker panels for the quantification of eight biomarkers related to drug-induced kidney damage, or nephrotoxicity.

2 Jul 2010

Immunosignature technique provides pre-symptomatic diagnosis for broad range of ailments

An inexpensive system for earlier disease diagnosis could save innumerable lives. It would also have a profound impact on the nation's healthcare industry, currently buckling under the strain of spiraling costs.

9 Jun 2010

Diagnosis of antiovarian autoantibodies in infertile women help in approaches for assisted reproduction

Studies on the ovarian antigens and its corresponding specific antibodies have showed the relationship between the incidences of antiovarian autoantibodies and the clinical mani-festation of ovarian dysfunction and infertility in women.

4 Jun 2010

Postdoctoral scientists receive NYSCF-Druckenmiller Fellowship award

The New York Stem Cell Foundation (NYSCF) today announced the award of eight new NYSCF-Druckenmiller Fellows. These postdoctoral scientists join 15 accomplished stem cell researchers from leading institutions who have been supported by the program since 2006. NYSCF has awarded 23 fellowships to date.

2 Jun 2010

VaxGen signs definitive agreement to acquire diaDexus in stock-for-stock merger

VaxGen, Inc., a biopharmaceutical company, and diaDexus, Inc., a privately held diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, announced today that they have entered into a definitive agreement under which VaxGen will acquire diaDexus in a stock-for-stock merger.

29 May 2010

ifp Institut für Produktqualität sells molecular biological, PCR-based food test product line to QIAGEN

The Berlin-based diagnostics company ifp Institut für Produktqualität has sold its molecular biological, PCR-based food test product line to QIAGEN at a price not revealed. QIAGEN has purchased all the required patents and licences and will immediately begin to market and distribute the newly acquired portfolio of 70 molecular biological tests. With the support of this powerful and experienced partner in food diagnostics ifp can now make available its expertise in food analytics globally.

From QIAGEN Manchester Limited 26 May 2010

IVAX Diagnostics first-quarter net revenues decline 1.4% to $4,655,000

IVAX Diagnostics, Inc., a fully integrated in vitro diagnostics company, reports its financial results for the quarter ended March 31, 2010.

14 May 2010

BioGenes study documents insufficient sensitivity of ELISA-based generic HCP assay

BioGenes GmbH, a supplier of GMP-compliant immunoassays and antibodies, completed a study that documents the insufficient sensitivity of an ELISA-based generic host cell protein assay. The results confirm the observation of several contract manufacturers that generic HCP assays are only of limited use for detection of HCPs during manufacturing processes.

12 May 2010

OriGene Technologies, ISB to create proteotypic PeptideAtlas and SRM/MRM mass spectrometry standard database

OriGene Technologies, Inc., a leading gene-centric life sciences company, and the Institute for Systems Biology (ISB), announce plans to create a proteotypic PeptideAtlas and develop an SRM/MRM (single reaction monitoring, multiple reaction monitoring) mass spectrometry standard database for 5,000 human proteins. The new collaboration will apply ISB's novel systems biology mass spectrometry expertise to OriGene's large collection of full length human proteins.

12 May 2010

Accuri Cytometers, eBioscience announce worldwide co-marketing agreement

Accuri Cytometers, Inc., the fastest growing life sciences company marketing and producing revolutionary bench-top flow cytometer systems, and eBioscience, the number two supplier of research flow cytometry reagents, today announced that they have entered into a worldwide co-marketing agreement.

10 May 2010

RayBiotech announces biomarker grant winners

RayBiotech, Inc. has announced the winners of its Biomarker Discovery Pilot Grant program. In total, 18 award recipients were chosen for grants of up to $20,000 each, redeemable for RayBiotech products and services. "By offering these grants," states Dr. Ray (Ruopan) Huang, Founder and President of RayBiotech, "we intend to demonstrate that any researcher with a modest research budget can successfully discover and validate disease-related biomarkers using our antibody arrays."

6 May 2010

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that a new blood test using the Company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial response in an initial set of patients treated with a combination of the antibody labeled with yttrium-90 (Y-90) and gemcitabine. Results were presented at the 101st Annual Meeting of the American Association for Cancer Research.

21 Apr 2010

APiX View Detection Kits available for ultra-sensitive chromogenic detection of protein microarrays

Gentel Biosciences, a leader in proteomics discovery tools, today announced the availability of the APiX View Detection Kits for ultra-sensitive chromogenic detection of protein microarrays, including reverse phase protein such as SomaPlex arrays from Protein Biotechnologies.

17 Apr 2010

Serametrix announces commercial launch of serum test for measuring serum antibodies

Serametrix has announced the commercial launch of a serum test for measuring serum antibodies to the important tumor antigen NY-ESO-1. The test will be offered as a service to drug companies and clinicians for correlative studies, monitoring and potentially predicting patient responses to cancer treatments.

16 Apr 2010

IVAX Diagnostics signs two-year distribution agreement with Biomerica

IVAX Diagnostics, Inc., a fully integrated in vitro diagnostics company, and Biomerica, Inc., a global biomedical company, have signed a two-year agreement for the distribution of Biomerica's products in the U.S. and globally, with certain country and product exclusions.

13 Apr 2010

Enrollment completes for Inovio Biomedical's dose escalation phase I trial of cervical cancer vaccine

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that the company has completed enrollment of all subjects for its therapeutic cervical cancer vaccine (VGX-3100) phase I trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18, and is delivered via in vivo electroporation.

8 Apr 2010